Anticoagulation in Stent Intervention

Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation

Objective:

The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg / day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2) who are undergoing PCI-S.

Design:

Randomized, parallel, with two arms, blind evaluation by third parties.

Patients:

304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2), which requires prevention of thrombosis

Inclusion Criteria:

• Patients of both sexes older than 18 years.
• Patients with permanent atrial fibrillation, persistent or paroxysmal (at least one episode), documented electrocardiographically and receiving oral anticoagulation. Patients with acute coronary syndrome or stable angina who are undergoing PCI-S.
• Patients who have previously given their informed consent to participation in the study.

Exclusion Criteria:

• Patients who can not be followed by the research team during the 12 months provided for monitoring.
• Patients with renal failure or serum creatinine above 2 mg • dL-1, neurological deficits, active ulcer or epigastric pain.
• Patients who continue regular treatment with NSAIDs or other analgesics or corticosteroids.
• Patients undergoing reoperation.
• Patients who during the study period, should receive, according to medical criteria, other adjuvant drug treatment than that specified in this protocol.
• Pregnant women.
• Use of investigational agents or not registered within 30 days of entry into the study.
• Patients with a history of allergy to study drugs or excipients.
• Patients with severe valve disease.
• Patients with CHADS> 2.
• Patients who can not use the study drug orally.